24 Results for "

KDM4A

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "KDM4A" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-125243
CAS No.: 2281766-67-2
Target:  

Histone Demethylase

Research Areas:  

Cancer

KDM5A-IN-2 is a KDM5A inhibitor. The human IC50 values of KDM5A-IN-2 for KDM5A, KDM5B, and KDM4A are 0.11 μM, 0.22 μM, and 5.3 μM, respectively. KDM5A-IN-2 inhibits KDM5B- and KDM4A-mediated histone lysine demethylation .
loading...
    loading...
Cat. No.: HY-P701619
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KDM4A; [Histone H3]-Trimethyl-L-Lysine(9) Demethylase 4A; Prev. JMJD2A; Lysine (K)-Specific Demethylase 4A; Prev. JMJD2; Lysine-Specific Demethylase 4A; JHDM3A; Jumonji Domain Containing 2A; KIAA0677; Tudor Domain Containing 14A; TDRD14A; Jumonji Domain C
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-104048R
CAS No.: 1851373-36-8
Research Areas:  

Cancer

QC6352 (Standard) is the analytical standard of QC6352 (HY-104048). This product is intended for research and analytical applications. QC6352 is an orally active KDM4 inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits KDM4 different isoforms with IC50s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against KDM5 with an IC50 of 750 nM (KDM5B) .
loading...
    loading...
Cat. No.: HY-183618
Research Areas:  

Cancer

DW-229 is a PROTAC degrader derived from Deferiprone (HY-B0568), targeting Fe(II)/α‑ketoglutarate‑dependent histone lysine demethylases (KDMs). DW-229 degrades KDM2A, KDM3A, KDM5B, KDM4A‑C, KDM5C, KDM6B in breast cancer cells. DW-229 shows IC50 < 0.5 μM against MCF‑7 cells and IC50 of 8.87 μM against MDA‑MB‑231 cells, with high cancer cell selectivity. DW-229 can be used for the research of breast cancer, liver cancer, prostate cancer, lung cancer .
loading...
    loading...